• Accumulated registered mums on the HeraMED platform at 4,282 as at 31 March 2025
• Collaboration agreement signed with Garmin Health to integrate smartwatch data into HeraCARE
• Advancement of pipeline with second commercial agreement in Florida nearing completion

HeraMED Limited (ASX:HMD) has provided its Appendix 4C cashflow statement for the March 2025 quarter (Q1 FY25) along with a review of operations. Key highlights include: Accumulated registered mums on the HeraCARE platform reached 4,282 as at 29 March 2025, with over 155,000 maternal vital measurements recorded. HeraMED signed a strategic collaboration agreement with Garmin Health to integrate smartwatch data into the HeraCARE platform, enhancing remote pregnancy monitoring. The company is nearing completion of a second commercial agreement with a large health system in Florida, building on the deployment at Broward Health. Early data from the Broward Health deployment is showing positive impacts on issues like preterm birth rates, hospital readmissions, and maternal/fetal outcomes. HeraMED continues to advance its grant funding strategy, with additional applications submitted in Australia. In Europe, the company is finalizing its first pilot agreement, while in Australia, partnerships with clinics like Simply Women, JOGG, and Melbourne Mothers continue to progress. HeraMED also appointed US-based healthcare executive Dr. Sharon R. Howell to its advisory board. Financially, the company had a cash balance of $1.884 million at the end of 2024, with key expenses including staff costs, R&D, and administration.

Looking ahead, HeraMED will continue to advance its product and data strategy, progress grant submissions to fund research and platform expansion, and deepen its commercial pipeline, particularly in the US and Europe.